Page 191 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg
P. 191
Cost analysis on DPYD genotype-guided dosing
17. Cortejoso L, Garcia-Gonzalez X, Garcia MI, Garcia-Alfonso P, Sanjurjo M, Lopez-Fernandez LA. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. Pharmacogenomics. 2016;17(9):979-984.
18. Murphy C, Byrne S, Ahmed G, et al. Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single- Institution Experience. Dose Response. 2018;16(4):1559325818803042.
19. Toffoli G, Innocenti F, Polesel J, et al. The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. Clin Pharmacol Ther. 2018.
20. Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415- 1424.
6
189
